XSTO
BACTIb
Market cap59mUSD
Jul 10, Last price
16.20SEK
1D
-1.82%
1Q
-3.57%
Jan 2017
-4.14%
IPO
-49.69%
Name
Bactiguard Holding AB
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Bactiguard Holding AB (publ), a Swedish-based global medical technology company, specializes in developing and supplying innovative solutions designed to prevent infections. Its primary objective is to mitigate healthcare-associated infections (HAIs) and reduce the global dependency on antibiotics. The core of Bactiguard's product line, known as Bactiguard Infection Protection (BIP), encompasses a range of coated medical devices. This includes various urinary catheters, such as the BIP Foley Catheter and the temperature-sensing BIP Foley TempSensor, all engineered to inhibit microbial adhesion and prevent urinary tract infections. Similarly, the BIP Central Venous Catheter and BIP Endotracheal Tube (with the BIP Endotracheal Tube Evac variant offering subglottic secretion drainage) work to reduce the risk of bloodstream and respiratory tract infections by minimizing biofilm formation. Beyond its BIP portfolio, the company offers a diverse array of other products, including Hydrocyn aqua advanced wound care for cleaning and debriding acute, chronic, and infected wounds, as well as general Bactiguard Wound Care items. It also provides a comprehensive selection of surgical sutures (natural absorbable, synthetic absorbable, non-absorbable, and specialty types), VigiMesh for hernia repair, and Hydrocyn aqua advanced disinfectant for sanitizing skin and surfaces. Additionally, Bactiguard supplies specialized orthopedic trauma implants featuring infection prevention technology under the ZNN Bactiguard brand, and the Aniocyn line of wound and skin care products for various pets. Bactiguard Holding AB (publ) was established in 2005 and maintains its headquarters in Tullinge, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||